Abstract
Sudden cardiac death (SCD) secondary to sudden cardiac arrest (SCA) is a leading cause of death in the United States, claiming over a quarter million lives annually, and is directly responsible for 50% of all cardiovascular mortality. Brugada Syndrome (BrS) is an arrhythmogenic cardiovascular channelopathy that predisposes asymptomatic patients who have no identified disease to a high-risk of SCD/SCA as their first cardiac event/disease manifestation. Limited progress has been made in risk prediction of SCA and SCD, with the greatest challenge being the ability to identify the small high-risk subgroups concealed within the larger general population. In conclusion, accurate identification of high-risk asymptomatic BrS patients (through multiparametric risk scores composed of reliable and validated unambiguous clinical variables and biomarkers) may hold utility in improving current SCD prediction algorithms, and the appropriate primary prevention therapy may prove valuable in reducing risk of sudden death for this patient population. This systematic review aims to comprehensively summarize qualitative evidence that explore proposed clinical, electrocardiographic, electrophysiological, and genetic markers for risk stratification of patients with BrS phenotype, and to discuss the best available contemporary evidence regarding therapeutic approach.
Collapse